PetCaseFinder

Peer-reviewed veterinary case report

Non-anticoagulant heparin reduces harmful blood cell clumping in dogs

By Guzmán, Maria A et al.·Published in Frontiers in veterinary science·2026·Department of Clinical Sciences, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Non-anticoagulant heparin attenuates histone-mediated platelet-leukocyte aggregation and neutrophil extracellular trap formation in a canine whole blood model.

Species:
dog

Plain-English summary

A group of healthy dogs was tested to see how two types of heparin, a blood-thinning medication, could help reduce inflammation caused by sepsis and systemic inflammatory response syndrome (SIRS). The study found that a specific type of heparin called non-anticoagulant heparin (NACH) significantly lowered the clumping of blood cells that can worsen these conditions. While another type, unfractionated heparin (UFH), also showed some benefits, NACH was more effective in reducing certain harmful blood cell interactions. This suggests that NACH could be a promising treatment option for managing inflammation in dogs with these serious health issues.

Abstract

INTRODUCTION: Sepsis and systemic inflammatory response syndrome (SIRS) are major contributors to morbidity and mortality in dogs, with limited therapeutic advancements. A key factor in this disease progression is the excessive formation of neutrophil extracellular traps (NETs). This study aimed to evaluate the ability of non-anticoagulant heparin (NACH) and unfractionated heparin (UFH) to modulate NET formation and platelet-leukocyte, platelet-neutrophil interactions in ancanine model of septic and aseptic inflammation. We hypothesized that NACH would be non-inferior to UFH in attenuating histone-mediated NET formation and platelet-leukocyte, platelet-neutrophil aggregate formations. METHODS: Eleven healthy staff-owned dogs were enrolled after confirmation of normal physical examinations and complete blood counts. Whole blood was collected and incubated with either calf thymus histone (0.5 mg/mL) or heated-killedO111:B4 (1 × 10) to simulate SIRS and sepsis, respectively. Samples were then treated with increasing concentrations of UFH (0, 0.4, 4 and 40 U/mL) or NACH (0, 1, 5, 10 μg/mL). Platelet-leukocyte and neutrophil-platelet aggregates were identified via flow cytometry using fluorophore-conjugated antibodies against platelets (CD61), leukocytes (CD18), and canine neutrophils. NET formation was assessed by quantifying cell-free DNA and intracellular citrullinated histones H3 (citH3) by flow cytometry. RESULTS: NACH at 10 μg/mL significantly reduced histone-induced platelet-leukocyte (29.0% ± 22.5) and platelet-neutrophil (22.7% ± 15.1) aggregates compared to vehicle controls (37.7% ± 23.7 and 31.8% ± 20.9; = 0.045). UFH did not significantly reduce histone-induced platelet-leukocyte interactions but showed a dose-dependent reduction in-induced platelet-leukocyte aggregates, with 40 IU/mL being the most effective (UFH 40 U/mL = 13.65%, IQR: 9.0 to 24.05 vs. UFH 0 U/mL = 18.10%, IQR: 12.68 to 36.18, = 0.047). Both NACH and UFH modulated neutrophil citH3 expression inmodel, but only high-dose NACH was able to module neutrophil extracellular trap formation in the histone mediated model. CONCLUSION: NACH effectively reduces histone-induced leukocyte and neutrophil-platelet aggregation, while UFH is more effective against-mediated responses. Both forms of heparin modulate NETs formation, highlighting their distinct stimulus-specific anti-inflammatory effects.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/42063423/